Curr Opin Immunol. 2025 Oct 4;97:102673. doi: 10.1016/j.coi.2025.102673. Online ahead of print.
ABSTRACT
Cutaneous involvement of sarcoidosis can provide important insights into the presence and prognosis of systemic involvement. Recent insights into the underlying pathophysiology of sarcoidosis have allowed for more targeted therapy, including inhibition of the JAK-STAT and mTOR pathways. In this review article, we discuss the epidemiology, clinical presentation, and pathophysiology of cutaneous sarcoidosis and delve into both traditional and evolving treatment strategies, with a focus on the association of therapy with our evolving understanding of sarcoidosis pathophysiology.
PMID:41046794 | DOI:10.1016/j.coi.2025.102673